You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 20, 2024

~ Buy the COSELA (trilaciclib dihydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

COSELA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cosela patents expire, and when can generic versions of Cosela launch?

Cosela is a drug marketed by G1 Therap and is included in one NDA. There are twelve patents protecting this drug.

This drug has one hundred and thirty-five patent family members in twenty-seven countries.

The generic ingredient in COSELA is trilaciclib dihydrochloride. One supplier is listed for this compound. Additional details are available on the trilaciclib dihydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Cosela

Cosela will be eligible for patent challenges on February 12, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for COSELA
International Patents:135
US Patents:12
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 25
Clinical Trials: 4
Drug Prices: Drug price information for COSELA
What excipients (inactive ingredients) are in COSELA?COSELA excipients list
DailyMed Link:COSELA at DailyMed
Drug patent expirations by year for COSELA
Drug Prices for COSELA

See drug prices for COSELA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for COSELA
Generic Entry Date for COSELA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for COSELA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wake Forest University Health SciencesPhase 2
Merck Sharp & Dohme LLCPhase 2
G1 Therapeutics, Inc.Phase 2

See all COSELA clinical trials

US Patents and Regulatory Information for COSELA

COSELA is protected by fifteen US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of COSELA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting COSELA

Transient protection of normal cells during chemotherapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER

CDK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

CDK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

CDK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Transient protection of normal cells during chemotherapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Transient protection of normal cells during chemotherapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER

Transient protection of normal cells during chemotherapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL CANCER


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER

CDK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

CDK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Transient protection of normal cells during chemotherapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Transient protection of normal cells during chemotherapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER

CDK inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting COSELA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
G1 Therap COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for COSELA

When does loss-of-exclusivity occur for COSELA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Patent: 06156
Estimated Expiration: ⤷  Sign Up

Patent: 06157
Estimated Expiration: ⤷  Sign Up

Patent: 06166
Estimated Expiration: ⤷  Sign Up

Patent: 52117
Estimated Expiration: ⤷  Sign Up

China

Patent: 5407723
Estimated Expiration: ⤷  Sign Up

Patent: 5407889
Estimated Expiration: ⤷  Sign Up

Patent: 5473140
Estimated Expiration: ⤷  Sign Up

Patent: 7417691
Estimated Expiration: ⤷  Sign Up

Patent: 8283644
Estimated Expiration: ⤷  Sign Up

Patent: 8434149
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0192168
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 22434
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 68290
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 67050
Estimated Expiration: ⤷  Sign Up

Patent: 68290
Estimated Expiration: ⤷  Sign Up

Patent: 68291
Estimated Expiration: ⤷  Sign Up

Patent: 53209
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 22766
Estimated Expiration: ⤷  Sign Up

Patent: 22792
Estimated Expiration: ⤷  Sign Up

Patent: 23293
Estimated Expiration: ⤷  Sign Up

Patent: 58477
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 46653
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 37083
Estimated Expiration: ⤷  Sign Up

Patent: 30483
Estimated Expiration: ⤷  Sign Up

Patent: 35315
Estimated Expiration: ⤷  Sign Up

Patent: 17401
Estimated Expiration: ⤷  Sign Up

Patent: 03583
Estimated Expiration: ⤷  Sign Up

Patent: 38933
Estimated Expiration: ⤷  Sign Up

Patent: 67456
Estimated Expiration: ⤷  Sign Up

Patent: 13854
Estimated Expiration: ⤷  Sign Up

Patent: 50737
Estimated Expiration: ⤷  Sign Up

Patent: 16513737
Estimated Expiration: ⤷  Sign Up

Patent: 16514689
Estimated Expiration: ⤷  Sign Up

Patent: 16518337
Estimated Expiration: ⤷  Sign Up

Patent: 18150333
Estimated Expiration: ⤷  Sign Up

Patent: 19055954
Estimated Expiration: ⤷  Sign Up

Patent: 19094324
Estimated Expiration: ⤷  Sign Up

Patent: 19131609
Estimated Expiration: ⤷  Sign Up

Patent: 20128408
Estimated Expiration: ⤷  Sign Up

Patent: 20183422
Estimated Expiration: ⤷  Sign Up

Patent: 21001197
Estimated Expiration: ⤷  Sign Up

Patent: 23052449
Estimated Expiration: ⤷  Sign Up

Patent: 23078341
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 68290
Estimated Expiration: ⤷  Sign Up

Montenegro

Patent: 557
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 68290
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 68290
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 790
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 68290
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 61406
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COSELA around the world.

Country Patent Number Title Estimated Expiration
Japan 2013543845 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2012061156 ⤷  Sign Up
Japan 2019055954 化学療法の間の正常細胞の一時的な保護 (TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY) ⤷  Sign Up
Russian Federation 2013123790 ИНГИБИТОРЫ CDK ⤷  Sign Up
South Korea 20240023677 화학요법 레지멘 동안의 면역 반응의 보존 (PRESERVATION OF IMMUNE RESPONSE DURING CHEMOTHERAPY REGIMENS) ⤷  Sign Up
Japan 6703583 ⤷  Sign Up
Israel 266870 שימור של תגובה חיסונית במהלך משטרי כימותרפיה (Preservation of immune response during chemotherapy regimens) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.